FRESENIUS SE: Helios Germany to recover by mid-2019 | BUY - Top Picks | EUR78 vs. EUR83
FRESENIUS SE - BUY - Top Picks | EUR78 vs. EUR83 (+48%)Helios Germany to recover by mid-2019
A mixed bag of expected and unexpected to remain until mid-19
Helios Germany folded but not broken
Usual language cautiousness on KABI
Longer than expected recovery for Helios, FV down to EUR78
Fresenius is a health care group providing products and services for dialysis, hospitals and outpatient medical care. Co. operates four business segments: Fresenius Medical Care; Fresenius Kabi; Fresenius Helios; and Fresenius Vamed. Fresenius Medical Care provides dialysis care and dialysis products for patients with chronic kidney failure. Fresenius Kabi is engaged in the provision of generic drugs, infusion therapies, clinical nutrition products, related medical devices and transfusion technology. Fresenius Vamed manages projects and provides services for hospitals and other health care facilities. Fresenius Helios is a private hospital operator which only operates in Germany.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.